NCT06883019

Lecanemab for Early Onset Familial Alzheimer's Disease

A Real World Study of Lecanemab Treatment in Participants with Early Onset Familial Alzheimer's Disease

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 114 (estimated)
• Sponsor: RenJi Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: —

Summary

The goal of this observational study is to learn about the efficacy of Lecanemab treatment for early-onset familial Alzheimer's disease (AD) in patients under 65 years of age with a family history of AD. Participants will receive Lecanemab at a dosage of 10 mg/kg every two weeks for a total of 18 months and will undergo cognitive assessments, PET and MRI scans, blood/fluid tests and whole genome sequencing. The study will explore the effects of genetic and hereditary factors on the efficacy of Lecanemab treatment in early-onset familial AD patients.

Conditions

• Alzheimer Disease

Timeline

• Start date: 2025-03-13
• Primary completion: 2027-06-30
• Completion: 2027-08-31
• First posted: 2025-03-19
• Last updated: 2025-03-19

Locations

15 sites across 1 country: China